Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trialsJADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic ...

The beefy yields on these instruments, issued mostly by European banks, have made them a magnet for investors. Owning AT1s can be fraught with risk, and they’re sometimes described as high-yield ...